| 0000-00-00 |
|
|
|
External link to document |
| 2016-08-08 |
234 |
Order |
ORDER CONSTRUING CLAIMS IN U.S. PATENT NO. 8,080,534. Signed by Judge Beth Labson Freeman on 8/… U.S. PATENT NO. 8,080,534
…infringement of U.S. Patent No. 8,080,534B2
21 (“the ’534 Patent”). The Court…the ’534 Patent.
23 I. BACKGROUND ON THE ’534 PATENT
…It is a ‘bedrock principle’ of patent law that ‘the claims of a patent define the
|
External link to document |
| 2016-09-22 |
257 |
Motion for Summary Judgment |
asserted claims 1, 2, and 8 of U.S. Patent No. 8,080,534 (the “'534 patent”) under
6 35 U.S.C. § 112…the '534 patent are invalid as a matter of law because the
12 '534 patent’s specification…genes. ('534
17 patent (ECF No. 21-1), 6:22-23.) The '534 patent purports to disclose the…disclosed in
13 the parent patent application. See Manual of Patent Examining Procedure § 201.08 (…STANDARD
5 Section 112 of the Patent Act requires that a patent include “a written description of |
External link to document |
| 2016-10-31 |
290 |
Order on Motion for Sanctions |
infringement of U.S. Patent No. 8,080,534
17 (“the ’534 patent”). ECF 21. …expression and thus infringes the ’534 patent. Id. Claim 1 of the ’534 patent is
…Plaintiff Phigenix, Inc. (“Phigenix”) brings this patent infringement lawsuit against
… 23 claims 1, 2, and 8 of the ’534 patent. ECF 21. Kadcyla comprises the antibody trastuzumab… to its
4 patent portfolio, and informed Genentech of its theory |
External link to document |
| 2017-02-23 |
327 |
Order on Motion for Summary Judgment |
infringes certain claims of U.S. Patent No. 8,080,534 (“the ’534 patent”) based on Kadcyla, a drug
…named inventor on numerous issued and pending patents and patent
25 applications… including the ’534 patent. First Am. Compl. (“FAC”) ¶ 1, ECF 21. The ’534 patent
… 27 3 (the ’534 patent). According to Phigenix, the ’534 patent describes and claims methods…cancer. ’534 patent
16 at 6:56-7:15. The ’534 patent also shows that |
External link to document |
| 2017-06-09 |
347 |
Motion for Summary Judgment |
asserted claims 1 and 21 of U.S. Patent No. 8,080,534 (the “’534 patent”) and
6 of invalidity under…infringed the patent. Genentech responded by pointing to Genentech’s
14 own prior art patent application… the
19 patent plainly lacks substantiating evidence, as all of the data in the patent pertains to… 271(b), the patent holder must prove “that the
9 alleged inducer knew of the patent, knowingly induced…alleged utility of the asserted patents . . . the burden shifts to [the patent holder] to present
23 evidence |
External link to document |
